Cat. No：GM-87757MAB
Product：Anti-VEGFxPD1 hIgG1 Reference Antibody (Ivobio)
Cat. No：GM-87757MAB
Product：Anti-VEGFxPD1 hIgG1 Reference Antibody (Ivobio)
GM-87757MAB-1mg / 1 mg
GM-87757MAB-5mg / 5 mg
GM-87757MAB-25mg / 25 mg
GM-87757MAB-50mg / 50 mg
GM-87757MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGF&PD1
Clone Ivonescimab
Alternative Names VEGF: VPF; MVCD1; L-VEGF PD1: CD279
Source/Isotype Monoclonal human IgG1, Kappa
Application /
Description PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.
Formulation phosphate-buffered solution, pH 7.4.
Cat. No：GM-87757MAB
Product：Anti-VEGFxPD1 hIgG1 Reference Antibody (Ivobio)
GM-87757MAB-1mg / 1 mg
GM-87757MAB-5mg / 5 mg
GM-87757MAB-25mg / 25 mg
GM-87757MAB-50mg / 50 mg
GM-87757MAB-100mg / 100 mg
Expression System CHO
Aggregation < 5% as determined by SEC-HPLC
Purity > 95% as determined by SDS-PAGE
Endotoxin < 1 EU/mg, determined by LAL gel clotting assay
Sterility 0.2 μm Filtered
Target VEGF&PD1
Clone Ivonescimab
Alternative Names VEGF: VPF; MVCD1; L-VEGF PD1: CD279
Source/Isotype Monoclonal human IgG1, Kappa
Application /
Description PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.
Formulation phosphate-buffered solution, pH 7.4.
